Amplifica Holdings Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $11.8M in Series A funding.
The company intends to use the funds to advance the development of its proprietary compounds for the treatment of androgenic alopecia (hair loss) in both male and female patients.
Led by CEO Frank Fazio, Amplifica is a biopharmaceutical company focused on developing novel treatments to address androgenic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The company, which is taking a nature-inspired scientific approach using a molecular mechanism that regrows natural hair, is focused on advancing the clinical development program for its lead product candidates AMP-303 and AMP-506 with the expectation to initiate the first clinical program in fiscal year 2023.
The Series A financing was facilitated by SternAegis Ventures, the private equity and venture capital division of Aegis Capital Corporation. SternAegis partners with entrepreneurs and early-stage companies to bring ideas to life, endeavoring to create brands with long-term investment value.